Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2026-03-23 Earnings Release
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Reports 2025 Financial Results and Provides Corporate Updat
Earnings Release Classification · 90% confidence The document is a press release titled “BioLineRx Reports 2025 Financial Results and Provides Corporate Update,” dated March 23, 2026, summarizing audited financial results for the year ended December 31, 2025, along with operational and clinical highlights and conference call details. It is not the full annual report (Form 20-F) itself but the initial public announcement of year‐end financial results. Such announcements fall under Earnings Release (ER). FY 2025
2026-03-23 English
Reports 2025 Financial Results and Provides Corporate Updat
Report Publication Announcement Classification · 90% confidence The text is an “Immediate Report” under Israel Securities Authority / Tel Aviv Stock Exchange rules indicating that a separate Form 6-K (the 2025 Financial Results and Corporate Update) is attached. The body includes no substantive financial data itself—just the notification that the report is published and attached. Under the “Menu vs. Meal” rule, short announcements stating a report “is attached” are classified as Report Publication Announcements (RPA).
2026-03-23 English
6-K - BioLineRx Ltd. (0001498403) (Filer)
Regulatory Filings
2026-03-23 English
20-F - BioLineRx Ltd. (0001498403) (Filer)
Annual Report FY 2025
2026-03-23 English
FORM 20-F For the fiscal year ended December 31, 2025
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) by BioLineRx Ltd. Form 20-F is the mandatory annual report for foreign private issuers, equivalent to the 10-K for domestic U.S. companies. The text explicitly identifies itself as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2025. It contains a table of contents, business overview, risk factors, and references to financial statements, confirming it is the full annual report rather than an announcement. FY 2025
2026-03-23 English
FORM 20-F For the fiscal year ended December 31, 2025
Report Publication Announcement Classification · 95% confidence The document is an “Immediate Report” under Israeli Securities Regulations announcing that “Attached hereto is a report on Form 20-F year 2025” and providing a PDF link. It does not include the full annual report content; it merely announces publication of the Form 20-F. According to the “menu vs. meal” rule, this is a report publication announcement rather than the report itself.
2026-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.